News | 30 October 2025
Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Tourmaline is now an indirect wholly owned subsidiary of Novartis
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
INEOS production of BDO in Germany, which produces a vital ingredient for antibiotics, statins and vitamin B6, is being crushed by a flood of carbon heavy imports and product dumping from the Far East
.jpg)
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025
The company’s “greener” initiatives emphasize eco-friendly excipients and energy-efficient manufacturing processes that reduce environmental impact without compromising product quality
The product is indicated for the chronic management of patients with Urea Cycle Disorders
Subscribe To Our Newsletter & Stay Updated
